title: Is attenuated COBRA treatment strategy (COBRA-light) non-inferior or not non-inferior than original COBRA strategy?
authors.affiliation: Izmir Katip Celebi University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey. servet.akar@gmail.com.
authors.forename: S
authors.initials: S
authors.lastname: Akar
authors.forename: M
authors.initials: M
authors.lastname: Tinazli
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use*; D012460:Sulfasalazine / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D012460:Sulfasalazine; D011239:Prednisolone; D008727:Methotrexate